

Endari™ (I-glutamine) - First-time generic

- On July 15, 2024, <u>ANI Pharmaceuticals launched</u> an <u>AA-rated</u> generic version of Emmaus Medical's Endari (I-glutamine) oral powder.
- Endari is approved to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.
- According to IQVIA[™], Endari had U.S. annual sales of \$20.1 million as of May 2024.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.